Home » Stocks » PHAS

PhaseBio Pharmaceuticals, Inc. (PHAS)

Stock Price: $4.33 USD 0.14 (3.34%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 127.15M
Revenue (ttm) 1.08M
Net Income (ttm) n/a
Shares Out 29.36M
EPS (ttm) -2.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $4.33
Previous Close $4.19
Change ($) 0.14
Change (%) 3.34%
Day's Open 4.16
Day's Range 4.16 - 4.38
Day's Volume 233,699
52-Week Range 2.68 - 6.02

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 days ago

PHAS has an interesting platform whose proof of concept lead asset has considerable chance of approval. If that molecule goes through, others may follow based on the ELP platform.

Zacks Investment Research - 1 week ago

Investors need to pay close attention to PhaseBio (PHAS) stock based on the movements in the options market lately.

Business Wire - 2 months ago

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results

Business Wire - 2 months ago

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

Business Wire - 3 months ago

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS--PhaseBio Provides Pemziviptadil (PB1046) Program Update

Business Wire - 3 months ago

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #PhaseBio--PhaseBio Doses First Patients in Canada as part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Ef...

Business Wire - 4 months ago

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Cardiology--PhaseBio to Present at the H.C.

Zacks Investment Research - 5 months ago

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -96.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Earnings--PhaseBio Pharmaceuticals Reports Recent Business Highlights and Second-Quarter 2020 Financial Results

Zacks Investment Research - 5 months ago

PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 5 months ago

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #ARDS--PhaseBio to Present at the William Blair Biotech Focus Conference 2020

Zacks Investment Research - 6 months ago

PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.

24/7 Wall Street - 6 months ago

PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) announced early on Friday that it has initiated its midstage study evaluating a treatment for the novel coronavirus.

Business Wire - 6 months ago

MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc.

Business Wire - 6 months ago

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #ARDS--PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

Forbes - 7 months ago

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify severa...

Other stocks mentioned: AGLE, DVAX, LQDA, SEEL
Zacks Investment Research - 7 months ago

PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.

Benzinga - 7 months ago

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) shares were skyrocketing Thursday after the company revealed it has received the go-ahead from the FDA for evaluating one of its lead assets for COV...

24/7 Wall Street - 7 months ago

PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) shares jumped early on Thursday after the company announced that it received an authorization from the U.S.

Zacks Investment Research - 8 months ago

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -26.83% and -14.67%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in PhaseBio Pharmaceuticals, Inc. (PHAS).

GlobeNewsWire - 11 months ago

MALVERN, Pa. and SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commerc...

GlobeNewsWire - 11 months ago

PB2452 granted PRIME Designation by the European Medicines Agency

GlobeNewsWire - 1 year ago

PhaseBio to be responsible for all development, manufacturing and commercialization PhaseBio to be responsible for all development, manufacturing and commercialization

Benzinga - 1 year ago

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS), which develops therapies for cardiopulmonary diseases, announced a financing agreement Friday that could provide the company with up to $120 millio...

GlobeNewsWire - 1 year ago

PhaseBio to receive up to $120 million in development funding

GlobeNewsWire - 1 year ago

MALVERN, Pa. and SAN DIEGO, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...

Zacks Investment Research - 1 year ago

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -11.11% and -31.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

GlobeNewsWire - 1 year ago

Company Appoints Kristopher L. Hanson as Vice President, Head of Legal and Glen Burkhardt as Vice President of Human Resources Company Appoints Kristopher L. Hanson as Vice President, Head of...

GlobeNewsWire - 1 year ago

MALVERN, Pa. and SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and comme...

GlobeNewsWire - 1 year ago

Preliminary Results from Supratherapeutic-Dose Ticagrelor Cohort Are Consistent with Earlier Phase 2a Cohorts and Previously Published Phase 1 Trial Preliminary Results from Supratherapeutic-D...

GlobeNewsWire - 1 year ago

Results from three different assays, including VerifyNow® PRUTest®, demonstrate a high degree of correlation Results from three different assays, including VerifyNow® PRUTest®, demonstrate a h...

GlobeNewsWire - 1 year ago

MALVERN, Pa. and SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commerc...

24/7 Wall Street - 1 year ago

Shares of PhaseBio Pharmaceuticals, Inc. jumped on Tuesday after the firm announced preliminary results from its mid-stage trial for dual antiplatelet therapy of the blood thinner ticagrelor a...

The Motley Fool - 1 year ago

Axsome Therapeutics and PhaseBio Pharmaceuticals are soaring this year, but the best could be yet to come for each of these red-hot biotech stocks.

Other stocks mentioned: AXSM
Seeking Alpha - 1 year ago

PhaseBio received Breakthrough Therapy Designation from the FDA based on positive phase 1 results using PB2452 as an anti-platelet agent for Brilinta.

The Motley Fool - 1 year ago

The company made two major announcements in the last 24 hours.

Zacks Investment Research - 1 year ago

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

24/7 Wall Street - 1 year ago

PhaseBio Pharmaceuticals Inc. shares made a sizable gain on Tuesday morning after the U.S. Food and Drug Administration provided a critical update for the firm.

Market Watch - 1 year ago

PhaseBio Pharmacueuticals Inc. shares rallied 28% in premarket trade Tuesday, after the company won U.S. Food and Drug Administration breakthrough therapy designation for PB2452, a novel rever...

The Motley Fool - 1 year ago

Can you guess what these high-flying stocks have in common?

Other stocks mentioned: AXSM, MGTA
Market Watch - 1 year ago

Shares of PhaseBio Pharmaceuticals Inc. more than doubled in premarket trade Monday, soaring 112% toward a record high.

24/7 Wall Street - 1 year ago

PhaseBio Pharmaceuticals Inc. shares more than doubled on Monday after the firm released results from an early-stage clinical trial.

Benzinga - 1 year ago

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

Other stocks mentioned: AMRN, AZN, JAZZ, LGND, LPTX, LXRX, RHHBY, SAGE, SBBP, SNY

About PHAS

PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial... [Read more...]

Industry
Biotechnology
IPO Date
Oct 18, 2018
CEO
Jonathan Mow
Employees
50
Stock Exchange
NASDAQ
Ticker Symbol
PHAS
Full Company Profile

Analyst Forecasts

According to 6 analysts, the average rating for PHAS stock is "Strong Buy." The 12-month stock price forecast is 13.50, which is an increase of 211.78% from the latest price.

Price Target
$13.50
(211.78% upside)
Analyst Consensus: Strong Buy